Ju Fu Tang Biotech Holdings Co., Ltd (HKG:8217)
Hong Kong · Delayed Price · Currency is HKD 0.1160
+0.0080 (7.41%)
Aug 4, 2026, 11:25 AM HKT
HKG:8217 Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 37.56 | 36.2 | 35.14 | 104.6 | 92.75 | |
Revenue Growth | 3.74% | 3.02% | -66.41% | 12.77% | -44.89% |
Cost of Revenue | 36.54 | 35.22 | 33.26 | 107.48 | 91.71 |
Gross Profit | 1.02 | 0.98 | 1.88 | -2.88 | 1.04 |
Selling, General & Admin | 8.53 | 9.35 | 7.57 | 5.8 | 10.63 |
Other Operating Expenses | -0.01 | -0.87 | -0.01 | -0.03 | -0.01 |
Operating Expenses | 7.27 | 12.23 | 6.12 | 9.79 | 22.55 |
Operating Income | -6.25 | -11.25 | -4.24 | -12.67 | -21.5 |
Interest Expense | -0.72 | -0.72 | -0.72 | -0.72 | -0.73 |
Other Non Operating Income (Expenses) | 0.1 | 0.2 | -0.36 | 0.02 | 0.34 |
EBT Excluding Unusual Items | -6.87 | -11.77 | -5.32 | -13.37 | -21.9 |
Gain (Loss) on Sale of Investments | 27.39 | 5.35 | -13.29 | -1.39 | 1.99 |
Gain (Loss) on Sale of Assets | 2.8 | - | - | 0.56 | 0.09 |
Asset Writedown | - | - | - | - | -0.51 |
Other Unusual Items | - | - | - | 0.51 | - |
Pretax Income | 23.32 | -5.9 | -17.43 | -9.96 | -20.21 |
Income Tax Expense | - | - | - | - | -0.06 |
Net Income | 23.32 | -5.9 | -17.43 | -9.96 | -20.15 |
Net Income to Common | 23.32 | -5.9 | -17.43 | -9.96 | -20.15 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 302 | 302 | 302 | 302 | 201 |
Shares Outstanding (Diluted) | 306 | 302 | 302 | 302 | 201 |
Shares Change | 1.33% | - | - | 50.37% | 131.26% |
EPS (Basic) | 0.08 | -0.02 | -0.06 | -0.03 | -0.10 |
EPS (Diluted) | 0.08 | -0.02 | -0.06 | -0.03 | -0.10 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -7.27 | 3.72 | 32.23 | -19.52 |
Free Cash Flow Per Share | - | -0.02 | 0.01 | 0.11 | -0.10 |
Gross Margin | 2.71% | 2.71% | 5.35% | -2.75% | 1.12% |
Operating Margin | -16.65% | -31.08% | -12.06% | -12.11% | -23.18% |
Profit Margin | 62.09% | -16.30% | -49.61% | -9.53% | -21.72% |
Free Cash Flow Margin | - | -20.08% | 10.59% | 30.81% | -21.04% |
EBITDA | -6.17 | -11.17 | -4.16 | -12.59 | -21.36 |
EBITDA Margin | -16.44% | -30.86% | -11.83% | -12.04% | -23.03% |
D&A For EBITDA | 0.08 | 0.08 | 0.08 | 0.08 | 0.14 |
EBIT | -6.25 | -11.25 | -4.24 | -12.67 | -21.5 |
EBIT Margin | -16.65% | -31.08% | -12.06% | -12.11% | -23.18% |